IPEX Syndrome

🏷

Classifications

Harrison's Chapter

IUIS Category

⚙

Pathophysiology

3

FOXP3 Loss and Regulatory T Cell Deficiency

Loss-of-function mutations in FOXP3 (scurfin), the lineage-defining forkhead transcription factor of regulatory T cells, impair the development and suppressive function of CD4+CD25+FOXP3+ Tregs. Most human mutations cluster in the forkhead (FKH) DNA-binding domain and abolish FOXP3 transcriptional output, so Tregs are often present but nonfunctional rather than numerically absent.

CD4+CD25+ regulatory T cell CL:0000815

regulatory T cell differentiation GO:0045066 ↓ DECREASED

Downstream

Loss of Peripheral Immune Tolerance Treg deficiency removes the dominant brake on autoreactive effector T cells.

Show evidence (2 references)

PMID:11137993 SUPPORT Human Clinical

"We present genetic evidence that different mutations of the human gene FOXP3, the ortholog of the gene mutated in scurfy mice (Foxp3), causes IPEX syndrome."

Establishes FOXP3 loss-of-function mutation as the molecular cause of IPEX.

PMID:33668198 SUPPORT Human Clinical

"the development and function of T regulatory cells are impaired, with an observed loss of CD4 + CD25 + T regulatory cells and uncontrolled proliferation of activated CD4 + effector cells"

Describes impaired Treg development/function as the proximal mechanism of IPEX.

Loss of Peripheral Immune Tolerance

Without functional Tregs, dominant peripheral tolerance fails and autoreactive CD4+ effector T cells proliferate uncontrolled. Patient T cells show marked skewing toward the Th2 phenotype, driving the allergic arm (eczema, elevated IgE, eosinophilia).

activated CD4+ effector T cell CL:0000911

tolerance induction GO:0002507 ↓ DECREASED negative regulation of immune response GO:0050777 ↓ DECREASED

Downstream

Multi-Organ Autoimmune Attack Unrestrained autoreactive lymphocytes and autoantibodies attack multiple organs.

Show evidence (2 references)

PMID:11120765 SUPPORT Human Clinical

"analysis of two kindreds with XLAAD revealed marked skewing of patient T lymphocytes toward the Th2 phenotype"

Documents the Th2 skew of effector T cells that follows loss of FOXP3-dependent regulation, underlying the atopic/allergic manifestations.

PMID:19410687 SUPPORT Human Clinical

"Treg cells maintain peripheral tolerance and protect the host from autoaggressive lymphocytes"

Explains that loss of Treg function removes peripheral tolerance, permitting autoaggressive lymphocytes.

Multi-Organ Autoimmune Attack

Autoreactive lymphocytes and autoantibodies target the intestine, pancreatic islets, skin, thyroid, kidney, liver, and blood cells, producing the enteropathy-endocrinopathy-dermatitis triad plus autoimmune cytopenias. Organ-specific autoantibodies (anti-enterocyte/anti-harmonin/anti-villin, anti-islet, anti-thyroid) mark the affected tissues.

CD4-positive helper T cell CL:0000492 enterocyte (autoimmune target in gut) CL:0000584 pancreatic beta cell (autoimmune target) CL:0000169

cytokine production GO:0001816 ↑ INCREASED

Show evidence (2 references)

PMID:33668198 SUPPORT Human Clinical

"The immune system attacks its own tissues and organs as a consequence of uncontrolled T cell activation, resulting in inflammation, autoimmunity, and metabolic disorders"

Describes the multi-organ autoimmune attack downstream of uncontrolled T cell activation.

PMID:11138001 SUPPORT Model Organism

"characterized by overproliferation of CD4+CD8- T lymphocytes, extensive multiorgan infiltration and elevation of numerous cytokines"

The scurfy (Foxp3-mutant) mouse recapitulates the multi-organ lymphocytic infiltration and cytokine elevation seen in IPEX (model-organism support).

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

17

Blood 4

Autoimmune Hemolytic Anemia OCCASIONAL Autoimmune hemolytic anemia HP:0001890

Show evidence (1 reference)

PMID:29241729 SUPPORT Human Clinical

"Hematological manifestations included autoimmune hemolytic anemia (25 of 96 patients)"

Autoimmune hemolytic anemia occurred in 25/96 (~26%) cohort patients, supporting the OCCASIONAL frequency band.

Autoimmune Thrombocytopenia OCCASIONAL Autoimmune thrombocytopenia HP:0001973

Show evidence (1 reference)

PMID:29241729 SUPPORT Human Clinical

"thrombocytopenia (13 of 96 patients)"

Thrombocytopenia occurred in 13/96 (~14%) cohort patients, supporting the OCCASIONAL frequency band.

Increased IgE FREQUENT Increased circulating IgE concentration HP:0003212

Show evidence (2 references)

PMID:11120765 SUPPORT Human Clinical

"manifestations of severe atopy including eczema, food allergy, and eosinophilic inflammation"

Documents the severe atopy (with eosinophilic inflammation) characterizing the allergic arm; elevated IgE is the serologic correlate.

PMID:33668198 SUPPORT Human Clinical

"Eosinophilia and elevated IgE level are typical."

Directly states that an elevated IgE level is typical of IPEX syndrome.

Eosinophilia FREQUENT Increased total eosinophil count HP:0001880

Show evidence (2 references)

PMID:11120765 SUPPORT Human Clinical

"manifestations of severe atopy including eczema, food allergy, and eosinophilic inflammation"

Documents eosinophilic inflammation as part of the atopic phenotype of IPEX/XLAAD.

PMID:33668198 SUPPORT Human Clinical

"Eosinophilia and elevated IgE level are typical."

Directly states that eosinophilia is typical of IPEX syndrome.

Cardiovascular 2

Lymphadenopathy OCCASIONAL Lymphadenopathy HP:0002716

Show evidence (1 reference)

PMID:20301297 SUPPORT Human Clinical

"many children have other autoimmune phenomena including cytopenias, autoimmune hepatitis, nephropathy, lymphadenopathy, splenomegaly, alopecia, arthritis, and interstitial lung disease"

GeneReviews lists lymphadenopathy among the additional autoimmune manifestations.

Splenomegaly Splenomegaly HP:0001744

Show evidence (1 reference)

PMID:20301297 SUPPORT Human Clinical

"many children have other autoimmune phenomena including cytopenias, autoimmune hepatitis, nephropathy, lymphadenopathy, splenomegaly, alopecia, arthritis, and interstitial lung disease"

GeneReviews lists splenomegaly among the additional autoimmune manifestations.

Digestive 1

Autoimmune Hepatitis OCCASIONAL Hepatitis HP:0012115

Show evidence (1 reference)

PMID:29241729 SUPPORT Human Clinical

"and hepatitis (19 of 96 patients)"

Hepatitis occurred in 19/96 (~20%) cohort patients, supporting the OCCASIONAL band.

Genitourinary 1

Nephropathy FREQUENT Nephropathy HP:0000112

Show evidence (1 reference)

PMID:29241729 SUPPORT Human Clinical

"nephropathy (autoimmune or secondary to malnutrition and medication) was the most common (33 of 96 patients)"

Nephropathy occurred in 33/96 (~34%) cohort patients, supporting the FREQUENT band.

Immune 3

Eczematous Dermatitis FREQUENT Eczematoid dermatitis HP:0000964

Show evidence (1 reference)

PMID:20301297 SUPPORT Human Clinical

"and eczematous dermatitis"

GeneReviews lists eczematous dermatitis as the dermatologic component of the IPEX triad.

Recurrent Infections FREQUENT Recurrent infections HP:0002719

Show evidence (1 reference)

PMID:20301297 SUPPORT Human Clinical

"the majority of affected males will die within the first one to two years of life from metabolic derangements, severe malabsorption, or sepsis"

GeneReviews documents sepsis as a major cause of death, reflecting the infection burden in IPEX.

Food Allergy OCCASIONAL Food allergy HP:0500093

Show evidence (2 references)

PMID:11120765 SUPPORT Human Clinical

"manifestations of severe atopy including eczema, food allergy, and eosinophilic inflammation"

Documents food allergy as part of the severe-atopy phenotype of IPEX/XLAAD.

PMID:29241729 SUPPORT Human Clinical

"food allergies (13 of 96 patients)"

Food allergies occurred in 13/96 (~14%) cohort patients, supporting the OCCASIONAL frequency band.

Growth 1

Failure to Thrive VERY_FREQUENT Failure to thrive HP:0001508

Show evidence (1 reference)

PMID:29241729 SUPPORT Human Clinical

"failure to thrive was a hallmark of the disease and it was sometimes the sole initial manifestation after 1 month of age"

Documents failure to thrive as a hallmark of IPEX.

Other 5

Autoimmune Enteropathy with Secretory Diarrhea VERY_FREQUENT Secretory diarrhea HP:0005208

Temporal: CHRONIC

Show evidence (2 references)

PMID:20301297 SUPPORT Human Clinical

"the triad of enteropathy (manifesting as malabsorption and watery diarrhea), endocrinopathy (most commonly type 1 insulin-dependent diabetes mellitus), and eczematous dermatitis"

GeneReviews defines enteropathy (malabsorption and watery diarrhea) as a cardinal component of the IPEX triad.

PMID:29241729 SUPPORT Human Clinical

"We confirm neonatal onset with enteropathy, type 1 diabetes, and eczema."

The international cohort confirms enteropathy as a near-universal neonatal-onset feature, supporting the VERY_FREQUENT band.

Villous Atrophy VERY_FREQUENT Villous atrophy HP:0011473

Show evidence (1 reference)

PMID:29241729 SUPPORT Human Clinical

"Villous atrophy remained the hallmark of IPEX enteropathy"

Documents villous atrophy as the histological hallmark of IPEX enteropathy.

Type 1 Diabetes Mellitus FREQUENT Type I diabetes mellitus HP:0100651

Show evidence (1 reference)

PMID:20301297 SUPPORT Human Clinical

"endocrinopathy (most commonly type 1 insulin-dependent diabetes mellitus)"

GeneReviews identifies type 1 insulin-dependent diabetes mellitus as the most common endocrinopathy in IPEX.

Autoimmune Thyroiditis OCCASIONAL Thyroiditis HP:0100646

Show evidence (1 reference)

PMID:29241729 SUPPORT Human Clinical

"Other conditions included autoimmune thyroiditis (15 of 96 patients)"

Autoimmune thyroiditis occurred in 15/96 (~16%) cohort patients, supporting the OCCASIONAL frequency band.

Autoimmune Neutropenia OCCASIONAL Autoimmune neutropenia HP:0001904

Show evidence (1 reference)

PMID:29241729 SUPPORT Human Clinical

"and neutropenia (6 of 96 patients)"

Neutropenia occurred in 6/96 (~6%) cohort patients, in the OCCASIONAL band (>=5%).

🧬

Genetic Associations

1

FOXP3 (Causative)

Gene: FOXP3 hgnc:6106 relationship_type: CAUSATIVE

X-linked recessive

Show evidence (4 references)

PMID:11137993 SUPPORT Human Clinical

"We present genetic evidence that different mutations of the human gene FOXP3, the ortholog of the gene mutated in scurfy mice (Foxp3), causes IPEX syndrome."

Direct genetic evidence that FOXP3 mutations cause IPEX.

PMID:11137992 SUPPORT Human Clinical

"Each mutation affects the forkhead/winged-helix domain of the scurfin protein, indicating that the mutations may disrupt critical DNA interactions."

Identifies the forkhead (FKH) DNA-binding domain as the mutational hotspot, disrupting DNA binding.

PMID:29241729 SUPPORT Human Clinical

"The forkhead (FKH) domain emerges as a mutational hotspot of the FOXP3 gene"

The 96-patient cohort confirms the FKH domain as a FOXP3 mutational hotspot.

+ 1 more reference

💊

Medical Actions

6

Sirolimus

Action: Pharmacotherapy NCIT:C15986

Agent: sirolimus CHEBI:9168

mTOR inhibitor and the preferred T-cell-directed immunosuppressant in IPEX, favored over calcineurin inhibitors because it is relatively Treg-sparing and can restore regulatory T cell function.

Mechanism Target:

INHIBITS Loss of Peripheral Immune Tolerance — Sirolimus suppresses autoreactive effector T cell proliferation and is relatively Treg-sparing, partially restoring peripheral tolerance.

Show evidence (1 reference)

PMID:20301297 SUPPORT Human Clinical

"T cell-directed immune suppression can include either an mTOR inhibitor (sirolimus) or calcineurin inhibitor (cyclosporin A or tacrolimus), alone or in combination with corticosteroids."

GeneReviews lists the mTOR inhibitor sirolimus as a T-cell-directed immunosuppressive option for IPEX.

Calcineurin Inhibitor Therapy

Action: Pharmacotherapy NCIT:C15986

Agent: tacrolimus CHEBI:61049 ciclosporin CHEBI:4031

Calcineurin inhibitors (tacrolimus or cyclosporin A) are alternative or adjunct T-cell-directed immunosuppressants, used alone or with corticosteroids.

Show evidence (1 reference)

PMID:20301297 SUPPORT Human Clinical

"calcineurin inhibitor (cyclosporin A or tacrolimus), alone or in combination with corticosteroids"

GeneReviews lists calcineurin inhibitors (cyclosporin A or tacrolimus) as a T-cell-directed immunosuppressive option for IPEX.

Corticosteroid Therapy

Action: Pharmacotherapy NCIT:C15986

Agent: corticosteroid CHEBI:50858

Corticosteroids are used, often in combination with an mTOR or calcineurin inhibitor, to control acute autoimmune flares.

Show evidence (1 reference)

PMID:20301297 SUPPORT Human Clinical

"alone or in combination with corticosteroids"

GeneReviews describes corticosteroids used in combination with T-cell-directed immunosuppression.

Allogeneic Hematopoietic Stem Cell Transplantation

Action: allogeneic hematopoietic stem cell transplantation MAXO:0001479

Allogeneic HSCT is the only established curative therapy for IPEX, restoring functional donor-derived Tregs (even mixed chimerism can suffice). Outcome is best when performed early, before organ damage accrues (low organ-involvement score).

Mechanism Target:

RESTORES FOXP3 Loss and Regulatory T Cell Deficiency — HSCT replaces the patient's hematopoietic system with donor cells capable of generating functional FOXP3+ regulatory T cells, correcting the primary defect.

Show evidence (3 references)

PMID:20301297 SUPPORT Human Clinical

"HSCT offers the only potential cure for IPEX syndrome."

GeneReviews states HSCT is the only potential cure for IPEX.

PMID:29241729 SUPPORT Human Clinical

"When performed in patients with a low OI score, HSCT resulted in disease resolution with better quality of life, independent of age, donor source, or conditioning regimen."

Cohort data show HSCT in low organ-involvement-score patients gives disease resolution, supporting it as the curative option and the value of early transplant.

PMID:20301297 SUPPORT Human Clinical

"Withhold immunizations until after HSCT, if possible."

GeneReviews Agents/Circumstances to Avoid: immunizations should be withheld until after HSCT where possible.

Total Parenteral Nutrition and Supportive Care

Action: total parenteral nutrition intake MAXO:0000114

Total parenteral nutrition with fluid and electrolyte support is needed for the enteropathy until intestinal function is re-established; supportive care also includes insulin for diabetes, thyroid hormone replacement, transfusions, and infection prophylaxis.

Show evidence (1 reference)

PMID:20301297 SUPPORT Human Clinical

"Total parenteral nutrition (TPN) with fluids and electrolyte support is needed until intestinal function can be established with immune suppression."

GeneReviews describes TPN with fluid/electrolyte support as needed supportive care for the enteropathy.

Insulin Replacement for Type 1 Diabetes

Action: Pharmacotherapy NCIT:C15986

Agent: insulin CHEBI:145810

Standard insulin therapy with carbohydrate management for the type 1 insulin-dependent diabetes component.

Show evidence (1 reference)

PMID:20301297 SUPPORT Human Clinical

"Treatment of type 1 insulin-dependent diabetes mellitus with insulin and carbohydrate management is standard"

GeneReviews describes standard insulin and carbohydrate management for the diabetes component.

🔬

Biochemical Markers

3

Elevated Serum IgE

Show evidence (1 reference)

PMID:11120765 SUPPORT Human Clinical

"manifestations of severe atopy including eczema, food allergy, and eosinophilic inflammation"

The severe-atopy phenotype (with eosinophilic inflammation) is reflected serologically in elevated IgE.

Anti-Enterocyte and Anti-Harmonin Autoantibodies

Show evidence (1 reference)

PMID:29241729 SUPPORT Human Clinical

"Antienterocyte, antiharmonin, or antivillin autoantibodies were positive in 33 of 42 patients with enteropathy tested"

Documents anti-enterocyte/anti-harmonin/anti-villin autoantibodies as enteropathy markers in the majority of tested patients.

Reduced or Dysfunctional Regulatory T Cells

Show evidence (1 reference)

PMID:29241729 SUPPORT Human Clinical

"The proportion of Treg cells, evaluated by flow cytometry, was available only in few patients and FOXP3 showed a wide range of expression."

Documents variable/reduced Treg proportion and wide-ranging FOXP3 expression on flow cytometry, the immunophenotypic hallmark.

🔀

Differential Diagnoses

2

Conditions with similar clinical presentations that must be differentiated from IPEX Syndrome:

APECED / Autoimmune Polyendocrine Syndrome Type 1 (AIRE)

Overlapping Features APECED/APS-1 is the key mechanistic contrast to IPEX. It is caused by AIRE mutations and reflects a defect in CENTRAL (thymic) tolerance, that is failed negative selection of autoreactive T cells in the thymus, whereas IPEX is a FOXP3/Treg defect in PERIPHERAL tolerance. APECED is autosomal recessive and presents with chronic mucocutaneous candidiasis, hypoparathyroidism, and adrenal insufficiency, rather than the neonatal enteropathy-diabetes-eczema triad of IPEX.

Show evidence (1 reference)

PMID:19410687 SUPPORT Human Clinical

"Other single-gene defects resulting in reduced Treg cell function include CD25, signal transducer and activator of transcription 5b, autoimmune regulator, and Wiskott-Aldrich syndrome protein."

Situates AIRE (autoimmune regulator) among the tolerance-related single-gene defects distinct from FOXP3, supporting the IPEX-vs-APECED differential.

IPEX-like Tregopathies (IL2RA/CD25, CTLA4, LRBA, STAT1-GOF, STAT3-GOF, STAT5B)

Overlapping Features "IPEX-like" syndromes phenocopy IPEX through other genes affecting Treg generation or function (CD25/IL2RA, CTLA4 haploinsufficiency, LRBA, STAT1 gain-of-function, STAT3 gain-of-function, STAT5B). They are the principal genetic differential diagnoses and are distinguished from true IPEX by the absence of a FOXP3 variant.

Show evidence (1 reference)

PMID:33668198 SUPPORT Human Clinical

"Those patients presented an X-like syndrome connected to other phenotype dysregulation genes: STAT5b, STAT1, STAT3, IL2RA, CTLA4, LRBA, TTC7A, TTC37, LRBA, and DOCK8"

Lists the IPEX-like genes that phenocopy IPEX without FOXP3 mutation, the key genetic differentials.

{ }

Source YAML

click to show

name: IPEX Syndrome
creation_date: "2026-06-30T00:00:00Z"
category: Mendelian
synonyms:
- Immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome
- X-linked autoimmunity-allergic dysregulation syndrome
- XLAAD
- XPID
- IDDM-secretory diarrhea syndrome
description: >
  IPEX (Immune dysregulation, Polyendocrinopathy, Enteropathy, X-linked)
  syndrome is a rare, X-linked recessive monogenic autoimmune disease caused by
  loss-of-function mutations in FOXP3, the master transcription factor required
  for the development and function of CD4+CD25+ regulatory T cells (Tregs). Loss
  of functional Tregs causes failure of dominant peripheral immune tolerance and
  aggressive multi-organ autoimmunity, typically presenting in infant boys in the
  first year of life. The classic triad is severe autoimmune enteropathy
  (intractable secretory/watery diarrhea, villous atrophy, failure to thrive),
  endocrinopathy (especially early-onset or neonatal type 1 diabetes mellitus and
  autoimmune thyroiditis), and eczematous dermatitis. Additional features include
  autoimmune cytopenias (Coombs-positive hemolytic anemia, thrombocytopenia,
  neutropenia), elevated serum IgE with eosinophilia and Th2 skewing, nephropathy,
  autoimmune hepatitis, lymphadenopathy, and recurrent infections. Untreated, IPEX
  is frequently fatal in infancy or early childhood. Immunosuppression
  (corticosteroids, calcineurin inhibitors, and the Treg-sparing mTOR inhibitor
  sirolimus) controls disease, but allogeneic hematopoietic stem cell
  transplantation is the only established curative therapy. Mechanistically, IPEX
  is the peripheral-tolerance (FOXP3/Treg) counterpart of APECED/APS-1, which is a
  central-thymic-tolerance defect caused by AIRE mutations.
disease_term:
  preferred_term: IPEX syndrome
  term:
    id: MONDO:0010580
    label: immune dysregulation-polyendocrinopathy-enteropathy-X-linked syndrome
parents:
- Primary immunodeficiency
- Autoimmune disease
references:
- reference: PMID:20301297
  title: "IPEX Syndrome."
  tags:
  - GeneReviews
classifications:
  harrisons_chapter:
  - classification_value: IMMUNE_RHEUMATOLOGIC
    evidence:
    - reference: PMID:19410687
      reference_title: "TH17 cells and regulatory T cells in primary immunodeficiency diseases."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Mutations in the FOXP3 gene interfere with Treg cell development and cause
        immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome.
      explanation: >-
        IPEX is an immune-mediated primary immunodeficiency/autoimmune disorder,
        the clinical home of the IMMUNE_RHEUMATOLOGIC part.
  - classification_value: GENETICS_ENVIRONMENT_DISEASE
    notes: >-
      IPEX is a monogenic, X-linked recessive Mendelian disorder, so the genetic
      part of Harrison's also applies.
  iuis_category:
    classification_value: immune dysregulation
    notes: >-
      In the IUIS inborn-errors-of-immunity classification IPEX is the prototypic
      "diseases of immune dysregulation" (Tregopathy) entity, caused by FOXP3
      mutation affecting regulatory T cells.
    evidence:
    - reference: PMID:29241729
      reference_title: "Long-term follow-up of IPEX syndrome patients after different therapeutic strategies: An international multicenter retrospective study."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Immunodysregulation polyendocrinopathy enteropathy x-linked (IPEX) syndrome
        is a monogenic autoimmune disease caused by FOXP3 mutations.
      explanation: >-
        Confirms IPEX as a monogenic immune-dysregulation disease of FOXP3, the IUIS
        "immune dysregulation" category.
pathophysiology:
- name: FOXP3 Loss and Regulatory T Cell Deficiency
  description: >
    Loss-of-function mutations in FOXP3 (scurfin), the lineage-defining forkhead
    transcription factor of regulatory T cells, impair the development and
    suppressive function of CD4+CD25+FOXP3+ Tregs. Most human mutations cluster in
    the forkhead (FKH) DNA-binding domain and abolish FOXP3 transcriptional
    output, so Tregs are often present but nonfunctional rather than numerically
    absent.
  cell_types:
  - preferred_term: CD4+CD25+ regulatory T cell
    term:
      id: CL:0000815
      label: regulatory T cell
  biological_processes:
  - preferred_term: regulatory T cell differentiation
    term:
      id: GO:0045066
      label: regulatory T cell differentiation
    modifier: DECREASED
  downstream:
  - target: Loss of Peripheral Immune Tolerance
    description: Treg deficiency removes the dominant brake on autoreactive effector T cells.
  evidence:
  - reference: PMID:11137993
    reference_title: "The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We present genetic evidence that different mutations of the human gene FOXP3,
      the ortholog of the gene mutated in scurfy mice (Foxp3), causes IPEX syndrome.
    explanation: >-
      Establishes FOXP3 loss-of-function mutation as the molecular cause of IPEX.
  - reference: PMID:33668198
    reference_title: "IPEX Syndrome: Genetics and Treatment Options."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      the development and function of T regulatory cells are impaired, with an
      observed loss of CD4 + CD25 + T regulatory cells and uncontrolled
      proliferation of activated CD4 + effector cells
    explanation: >-
      Describes impaired Treg development/function as the proximal mechanism of IPEX.
- name: Loss of Peripheral Immune Tolerance
  description: >
    Without functional Tregs, dominant peripheral tolerance fails and autoreactive
    CD4+ effector T cells proliferate uncontrolled. Patient T cells show marked
    skewing toward the Th2 phenotype, driving the allergic arm (eczema, elevated
    IgE, eosinophilia).
  cell_types:
  - preferred_term: activated CD4+ effector T cell
    term:
      id: CL:0000911
      label: effector T cell
  biological_processes:
  - preferred_term: tolerance induction
    term:
      id: GO:0002507
      label: tolerance induction
    modifier: DECREASED
  - preferred_term: negative regulation of immune response
    term:
      id: GO:0050777
      label: negative regulation of immune response
    modifier: DECREASED
  downstream:
  - target: Multi-Organ Autoimmune Attack
    description: Unrestrained autoreactive lymphocytes and autoantibodies attack multiple organs.
  evidence:
  - reference: PMID:11120765
    reference_title: "JM2, encoding a fork head-related protein, is mutated in X-linked autoimmunity-allergic disregulation syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      analysis of two kindreds with XLAAD revealed marked skewing of patient T
      lymphocytes toward the Th2 phenotype
    explanation: >-
      Documents the Th2 skew of effector T cells that follows loss of FOXP3-dependent
      regulation, underlying the atopic/allergic manifestations.
  - reference: PMID:19410687
    reference_title: "TH17 cells and regulatory T cells in primary immunodeficiency diseases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Treg cells maintain peripheral tolerance and protect the host from
      autoaggressive lymphocytes
    explanation: >-
      Explains that loss of Treg function removes peripheral tolerance, permitting
      autoaggressive lymphocytes.
- name: Multi-Organ Autoimmune Attack
  description: >
    Autoreactive lymphocytes and autoantibodies target the intestine, pancreatic
    islets, skin, thyroid, kidney, liver, and blood cells, producing the
    enteropathy-endocrinopathy-dermatitis triad plus autoimmune cytopenias.
    Organ-specific autoantibodies (anti-enterocyte/anti-harmonin/anti-villin,
    anti-islet, anti-thyroid) mark the affected tissues.
  cell_types:
  - preferred_term: CD4-positive helper T cell
    term:
      id: CL:0000492
      label: CD4-positive helper T cell
  - preferred_term: enterocyte (autoimmune target in gut)
    term:
      id: CL:0000584
      label: enterocyte
  - preferred_term: pancreatic beta cell (autoimmune target)
    term:
      id: CL:0000169
      label: type B pancreatic cell
  biological_processes:
  - preferred_term: cytokine production
    term:
      id: GO:0001816
      label: cytokine production
    modifier: INCREASED
  evidence:
  - reference: PMID:33668198
    reference_title: "IPEX Syndrome: Genetics and Treatment Options."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The immune system attacks its own tissues and organs as a consequence of
      uncontrolled T cell activation, resulting in inflammation, autoimmunity, and
      metabolic disorders
    explanation: >-
      Describes the multi-organ autoimmune attack downstream of uncontrolled T cell
      activation.
  - reference: PMID:11138001
    reference_title: "Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      characterized by overproliferation of CD4+CD8- T lymphocytes, extensive
      multiorgan infiltration and elevation of numerous cytokines
    explanation: >-
      The scurfy (Foxp3-mutant) mouse recapitulates the multi-organ lymphocytic
      infiltration and cytokine elevation seen in IPEX (model-organism support).
phenotypes:
- name: Autoimmune Enteropathy with Secretory Diarrhea
  description: >
    Severe autoimmune enteropathy with intractable secretory/watery diarrhea and
    malabsorption. The most consistent and typically the presenting, and often
    life-threatening, manifestation.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Secretory diarrhea
    term:
      id: HP:0005208
      label: Secretory diarrhea
    temporality: CHRONIC
  evidence:
  - reference: PMID:20301297
    reference_title: "IPEX Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      the triad of enteropathy (manifesting as malabsorption and watery diarrhea),
      endocrinopathy (most commonly type 1 insulin-dependent diabetes mellitus), and
      eczematous dermatitis
    explanation: >-
      GeneReviews defines enteropathy (malabsorption and watery diarrhea) as a
      cardinal component of the IPEX triad.
  - reference: PMID:29241729
    reference_title: "Long-term follow-up of IPEX syndrome patients after different therapeutic strategies: An international multicenter retrospective study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We confirm neonatal onset with enteropathy, type 1 diabetes, and eczema.
    explanation: >-
      The international cohort confirms enteropathy as a near-universal neonatal-onset
      feature, supporting the VERY_FREQUENT band.
- name: Villous Atrophy
  description: >
    Small-bowel villous atrophy is the histological hallmark of IPEX enteropathy,
    with a polymorphic lymphocyte- and eosinophil-rich lamina propria infiltrate.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Villous atrophy
    term:
      id: HP:0011473
      label: Villous atrophy
  evidence:
  - reference: PMID:29241729
    reference_title: "Long-term follow-up of IPEX syndrome patients after different therapeutic strategies: An international multicenter retrospective study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Villous atrophy remained the hallmark of IPEX enteropathy
    explanation: >-
      Documents villous atrophy as the histological hallmark of IPEX enteropathy.
- name: Type 1 Diabetes Mellitus
  description: >
    Early-onset or neonatal autoimmune type 1 diabetes mellitus from immune
    destruction of pancreatic beta cells; the most common endocrinopathy and often
    the earliest endocrine sign.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Type 1 diabetes mellitus
    term:
      id: HP:0100651
      label: Type I diabetes mellitus
  evidence:
  - reference: PMID:20301297
    reference_title: "IPEX Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      endocrinopathy (most commonly type 1 insulin-dependent diabetes mellitus)
    explanation: >-
      GeneReviews identifies type 1 insulin-dependent diabetes mellitus as the most
      common endocrinopathy in IPEX.
- name: Eczematous Dermatitis
  description: >
    Eczematous (atopic-like), and sometimes erythrodermic, psoriasiform, or
    ichthyosiform, dermatitis; the third component of the classic triad.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Eczematoid dermatitis
    term:
      id: HP:0000964
      label: Eczematoid dermatitis
  evidence:
  - reference: PMID:20301297
    reference_title: "IPEX Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      and eczematous dermatitis
    explanation: >-
      GeneReviews lists eczematous dermatitis as the dermatologic component of the
      IPEX triad.
- name: Autoimmune Thyroiditis
  description: >
    Autoimmune thyroiditis (typically hypothyroidism, sometimes hyperthyroidism),
    a frequent endocrine manifestation.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Thyroiditis
    term:
      id: HP:0100646
      label: Thyroiditis
  evidence:
  - reference: PMID:29241729
    reference_title: "Long-term follow-up of IPEX syndrome patients after different therapeutic strategies: An international multicenter retrospective study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Other conditions included autoimmune thyroiditis (15 of 96 patients)
    explanation: >-
      Autoimmune thyroiditis occurred in 15/96 (~16%) cohort patients, supporting the
      OCCASIONAL frequency band.
- name: Autoimmune Hemolytic Anemia
  description: >
    Coombs-positive autoimmune hemolytic anemia, the most common hematologic
    autoimmune manifestation.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Autoimmune hemolytic anemia
    term:
      id: HP:0001890
      label: Autoimmune hemolytic anemia
  evidence:
  - reference: PMID:29241729
    reference_title: "Long-term follow-up of IPEX syndrome patients after different therapeutic strategies: An international multicenter retrospective study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Hematological manifestations included autoimmune hemolytic anemia (25 of 96 patients)
    explanation: >-
      Autoimmune hemolytic anemia occurred in 25/96 (~26%) cohort patients, supporting
      the OCCASIONAL frequency band.
- name: Autoimmune Thrombocytopenia
  description: >
    Autoimmune thrombocytopenia, part of the spectrum of autoimmune cytopenias.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Autoimmune thrombocytopenia
    term:
      id: HP:0001973
      label: Autoimmune thrombocytopenia
  evidence:
  - reference: PMID:29241729
    reference_title: "Long-term follow-up of IPEX syndrome patients after different therapeutic strategies: An international multicenter retrospective study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      thrombocytopenia (13 of 96 patients)
    explanation: >-
      Thrombocytopenia occurred in 13/96 (~14%) cohort patients, supporting the
      OCCASIONAL frequency band.
- name: Autoimmune Neutropenia
  description: >
    Autoimmune neutropenia, another of the autoimmune cytopenias, sometimes managed
    with granulocyte colony-stimulating factor.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Autoimmune neutropenia
    term:
      id: HP:0001904
      label: Autoimmune neutropenia
  evidence:
  - reference: PMID:29241729
    reference_title: "Long-term follow-up of IPEX syndrome patients after different therapeutic strategies: An international multicenter retrospective study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      and neutropenia (6 of 96 patients)
    explanation: >-
      Neutropenia occurred in 6/96 (~6%) cohort patients, in the OCCASIONAL band (>=5%).
- name: Nephropathy
  description: >
    Renal involvement ranging from proteinuria, nephrocalcinosis, and tubulopathy
    to interstitial nephritis and nephrotic syndrome; autoimmune or secondary to
    malnutrition and medication.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Nephropathy
    term:
      id: HP:0000112
      label: Nephropathy
  evidence:
  - reference: PMID:29241729
    reference_title: "Long-term follow-up of IPEX syndrome patients after different therapeutic strategies: An international multicenter retrospective study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      nephropathy (autoimmune or secondary to malnutrition and medication) was the
      most common (33 of 96 patients)
    explanation: >-
      Nephropathy occurred in 33/96 (~34%) cohort patients, supporting the FREQUENT band.
- name: Autoimmune Hepatitis
  description: >
    Autoimmune hepatitis / liver involvement, sometimes an atypical later-onset
    presentation.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Hepatitis
    term:
      id: HP:0012115
      label: Hepatitis
  evidence:
  - reference: PMID:29241729
    reference_title: "Long-term follow-up of IPEX syndrome patients after different therapeutic strategies: An international multicenter retrospective study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      and hepatitis (19 of 96 patients)
    explanation: >-
      Hepatitis occurred in 19/96 (~20%) cohort patients, supporting the OCCASIONAL band.
- name: Failure to Thrive
  description: >
    Failure to thrive is a hallmark of IPEX, sometimes the sole initial
    manifestation after the first month of life, largely secondary to the
    enteropathy and malabsorption.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Failure to thrive
    term:
      id: HP:0001508
      label: Failure to thrive
  evidence:
  - reference: PMID:29241729
    reference_title: "Long-term follow-up of IPEX syndrome patients after different therapeutic strategies: An international multicenter retrospective study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      failure to thrive was a hallmark of the disease and it was sometimes the sole
      initial manifestation after 1 month of age
    explanation: >-
      Documents failure to thrive as a hallmark of IPEX.
- name: Increased IgE
  description: >
    Markedly elevated serum IgE, part of the atopic/Th2-skewed laboratory profile.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Increased circulating IgE concentration
    term:
      id: HP:0003212
      label: Increased circulating IgE concentration
  evidence:
  - reference: PMID:11120765
    reference_title: "JM2, encoding a fork head-related protein, is mutated in X-linked autoimmunity-allergic disregulation syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      manifestations of severe atopy including eczema, food allergy, and
      eosinophilic inflammation
    explanation: >-
      Documents the severe atopy (with eosinophilic inflammation) characterizing the
      allergic arm; elevated IgE is the serologic correlate.
  - reference: PMID:33668198
    reference_title: "IPEX Syndrome: Genetics and Treatment Options."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Eosinophilia and elevated IgE level are typical.
    explanation: >-
      Directly states that an elevated IgE level is typical of IPEX syndrome.
- name: Eosinophilia
  description: >
    Peripheral eosinophilia reflecting the Th2-skewed allergic inflammation.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Increased total eosinophil count
    term:
      id: HP:0001880
      label: Increased total eosinophil count
  evidence:
  - reference: PMID:11120765
    reference_title: "JM2, encoding a fork head-related protein, is mutated in X-linked autoimmunity-allergic disregulation syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      manifestations of severe atopy including eczema, food allergy, and
      eosinophilic inflammation
    explanation: >-
      Documents eosinophilic inflammation as part of the atopic phenotype of IPEX/XLAAD.
  - reference: PMID:33668198
    reference_title: "IPEX Syndrome: Genetics and Treatment Options."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Eosinophilia and elevated IgE level are typical.
    explanation: >-
      Directly states that eosinophilia is typical of IPEX syndrome.
- name: Recurrent Infections
  description: >
    Recurrent and severe infections/sepsis from immune dysregulation, skin/gut
    barrier breakdown, central venous access, and iatrogenic immunosuppression; a
    leading cause of death.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Recurrent infections
    term:
      id: HP:0002719
      label: Recurrent infections
  evidence:
  - reference: PMID:20301297
    reference_title: "IPEX Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      the majority of affected males will die within the first one to two years of
      life from metabolic derangements, severe malabsorption, or sepsis
    explanation: >-
      GeneReviews documents sepsis as a major cause of death, reflecting the infection
      burden in IPEX.
- name: Lymphadenopathy
  description: >
    Lymphadenopathy occurring during disease progression.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Lymphadenopathy
    term:
      id: HP:0002716
      label: Lymphadenopathy
  evidence:
  - reference: PMID:20301297
    reference_title: "IPEX Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      many children have other autoimmune phenomena including cytopenias, autoimmune
      hepatitis, nephropathy, lymphadenopathy, splenomegaly, alopecia, arthritis, and
      interstitial lung disease
    explanation: >-
      GeneReviews lists lymphadenopathy among the additional autoimmune manifestations.
- name: Food Allergy
  description: >
    Food allergy, part of the atopic/Th2-skewed spectrum and reported during the
    disease course.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Food allergy
    term:
      id: HP:0500093
      label: Food allergy
  evidence:
  - reference: PMID:11120765
    reference_title: "JM2, encoding a fork head-related protein, is mutated in X-linked autoimmunity-allergic disregulation syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      manifestations of severe atopy including eczema, food allergy, and
      eosinophilic inflammation
    explanation: >-
      Documents food allergy as part of the severe-atopy phenotype of IPEX/XLAAD.
  - reference: PMID:29241729
    reference_title: "Long-term follow-up of IPEX syndrome patients after different therapeutic strategies: An international multicenter retrospective study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      food allergies (13 of 96 patients)
    explanation: >-
      Food allergies occurred in 13/96 (~14%) cohort patients, supporting the
      OCCASIONAL frequency band.
- name: Splenomegaly
  description: >
    Splenomegaly is among the additional autoimmune/lymphoproliferative
    manifestations of IPEX.
  phenotype_term:
    preferred_term: Splenomegaly
    term:
      id: HP:0001744
      label: Splenomegaly
  evidence:
  - reference: PMID:20301297
    reference_title: "IPEX Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      many children have other autoimmune phenomena including cytopenias, autoimmune
      hepatitis, nephropathy, lymphadenopathy, splenomegaly, alopecia, arthritis, and
      interstitial lung disease
    explanation: >-
      GeneReviews lists splenomegaly among the additional autoimmune manifestations.
genetic:
- name: FOXP3
  gene_term:
    preferred_term: FOXP3
    term:
      id: hgnc:6106
      label: FOXP3
  association: Causative
  relationship_type: CAUSATIVE
  inheritance:
  - name: X-linked recessive
    inheritance_term:
      preferred_term: X-linked recessive inheritance
      term:
        id: HP:0001419
        label: X-linked recessive inheritance
  notes: >
    Hemizygous loss-of-function variants in FOXP3 (Xp11.23) cause IPEX. FOXP3
    encodes scurfin, a 431-aa forkhead/winged-helix transcription factor; the
    forkhead (FKH) DNA-binding domain is a mutational hotspot. Variant classes
    include missense, nonsense, frameshift, splice-site, and polyadenylation-signal
    variants; most are loss-of-function, some hypomorphic. Affected individuals are
    almost exclusively hemizygous males; carrier females are typically asymptomatic.
  evidence:
  - reference: PMID:11137993
    reference_title: "The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We present genetic evidence that different mutations of the human gene FOXP3,
      the ortholog of the gene mutated in scurfy mice (Foxp3), causes IPEX syndrome.
    explanation: >-
      Direct genetic evidence that FOXP3 mutations cause IPEX.
  - reference: PMID:11137992
    reference_title: "X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Each mutation affects the forkhead/winged-helix domain of the scurfin protein,
      indicating that the mutations may disrupt critical DNA interactions.
    explanation: >-
      Identifies the forkhead (FKH) DNA-binding domain as the mutational hotspot,
      disrupting DNA binding.
  - reference: PMID:29241729
    reference_title: "Long-term follow-up of IPEX syndrome patients after different therapeutic strategies: An international multicenter retrospective study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The forkhead (FKH) domain emerges as a mutational hotspot of the FOXP3 gene
    explanation: >-
      The 96-patient cohort confirms the FKH domain as a FOXP3 mutational hotspot.
  - reference: PMID:20301297
    reference_title: "IPEX Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      If the mother of the proband has a FOXP3 pathogenic variant, the chance of
      transmitting the pathogenic variant in each pregnancy is 50%.
    explanation: >-
      GeneReviews Genetic Counseling: X-linked transmission with 50% risk per pregnancy
      from a carrier mother; affected males inherit the variant, females become carriers.
biochemical:
- name: Elevated Serum IgE
  notes: >
    Markedly elevated serum IgE is characteristic of the Th2-skewed atopic profile
    of IPEX.
  evidence:
  - reference: PMID:11120765
    reference_title: "JM2, encoding a fork head-related protein, is mutated in X-linked autoimmunity-allergic disregulation syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      manifestations of severe atopy including eczema, food allergy, and
      eosinophilic inflammation
    explanation: >-
      The severe-atopy phenotype (with eosinophilic inflammation) is reflected
      serologically in elevated IgE.
- name: Anti-Enterocyte and Anti-Harmonin Autoantibodies
  notes: >
    Anti-enterocyte, anti-harmonin (AIE-75), and anti-villin autoantibodies are
    relatively specific serological markers of the IPEX enteropathy.
  evidence:
  - reference: PMID:29241729
    reference_title: "Long-term follow-up of IPEX syndrome patients after different therapeutic strategies: An international multicenter retrospective study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Antienterocyte, antiharmonin, or antivillin autoantibodies were positive in
      33 of 42 patients with enteropathy tested
    explanation: >-
      Documents anti-enterocyte/anti-harmonin/anti-villin autoantibodies as enteropathy
      markers in the majority of tested patients.
- name: Reduced or Dysfunctional Regulatory T Cells
  notes: >
    Flow cytometry of CD4+CD25+CD127-low Tregs and FOXP3 protein shows absent,
    reduced, or present-but-dysfunctional Tregs; FOXP3 expression varies widely.
  evidence:
  - reference: PMID:29241729
    reference_title: "Long-term follow-up of IPEX syndrome patients after different therapeutic strategies: An international multicenter retrospective study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The proportion of Treg cells, evaluated by flow cytometry, was available only
      in few patients and FOXP3 showed a wide range of expression.
    explanation: >-
      Documents variable/reduced Treg proportion and wide-ranging FOXP3 expression on
      flow cytometry, the immunophenotypic hallmark.
treatments:
- name: Sirolimus
  description: >
    mTOR inhibitor and the preferred T-cell-directed immunosuppressant in IPEX,
    favored over calcineurin inhibitors because it is relatively Treg-sparing and
    can restore regulatory T cell function.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: sirolimus
      term:
        id: CHEBI:9168
        label: sirolimus
  target_mechanisms:
  - target: Loss of Peripheral Immune Tolerance
    treatment_effect: INHIBITS
    description: >-
      Sirolimus suppresses autoreactive effector T cell proliferation and is
      relatively Treg-sparing, partially restoring peripheral tolerance.
  evidence:
  - reference: PMID:20301297
    reference_title: "IPEX Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      T cell-directed immune suppression can include either an mTOR inhibitor
      (sirolimus) or calcineurin inhibitor (cyclosporin A or tacrolimus), alone or in
      combination with corticosteroids.
    explanation: >-
      GeneReviews lists the mTOR inhibitor sirolimus as a T-cell-directed
      immunosuppressive option for IPEX.
- name: Calcineurin Inhibitor Therapy
  description: >
    Calcineurin inhibitors (tacrolimus or cyclosporin A) are alternative or adjunct
    T-cell-directed immunosuppressants, used alone or with corticosteroids.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: tacrolimus
      term:
        id: CHEBI:61049
        label: tacrolimus (anhydrous)
    - preferred_term: ciclosporin
      term:
        id: CHEBI:4031
        label: cyclosporin A
  evidence:
  - reference: PMID:20301297
    reference_title: "IPEX Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      calcineurin inhibitor (cyclosporin A or tacrolimus), alone or in combination
      with corticosteroids
    explanation: >-
      GeneReviews lists calcineurin inhibitors (cyclosporin A or tacrolimus) as a
      T-cell-directed immunosuppressive option for IPEX.
- name: Corticosteroid Therapy
  description: >
    Corticosteroids are used, often in combination with an mTOR or calcineurin
    inhibitor, to control acute autoimmune flares.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: corticosteroid
      term:
        id: CHEBI:50858
        label: corticosteroid
  evidence:
  - reference: PMID:20301297
    reference_title: "IPEX Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      alone or in combination with corticosteroids
    explanation: >-
      GeneReviews describes corticosteroids used in combination with T-cell-directed
      immunosuppression.
- name: Allogeneic Hematopoietic Stem Cell Transplantation
  description: >
    Allogeneic HSCT is the only established curative therapy for IPEX, restoring
    functional donor-derived Tregs (even mixed chimerism can suffice). Outcome is
    best when performed early, before organ damage accrues (low organ-involvement
    score).
  notes: >
    Agents/circumstances to avoid (GeneReviews): withhold immunizations until after
    HSCT, if possible, given the immune dysregulation and peri-transplant
    immunosuppression.
  therapeutic_modality: CELL_THERAPY
  treatment_term:
    preferred_term: allogeneic hematopoietic stem cell transplantation
    term:
      id: MAXO:0001479
      label: allogeneic hematopoietic stem cell transplantation
  target_mechanisms:
  - target: FOXP3 Loss and Regulatory T Cell Deficiency
    treatment_effect: RESTORES
    description: >-
      HSCT replaces the patient's hematopoietic system with donor cells capable of
      generating functional FOXP3+ regulatory T cells, correcting the primary defect.
  evidence:
  - reference: PMID:20301297
    reference_title: "IPEX Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      HSCT offers the only potential cure for IPEX syndrome.
    explanation: >-
      GeneReviews states HSCT is the only potential cure for IPEX.
  - reference: PMID:29241729
    reference_title: "Long-term follow-up of IPEX syndrome patients after different therapeutic strategies: An international multicenter retrospective study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      When performed in patients with a low OI score, HSCT resulted in disease
      resolution with better quality of life, independent of age, donor source, or
      conditioning regimen.
    explanation: >-
      Cohort data show HSCT in low organ-involvement-score patients gives disease
      resolution, supporting it as the curative option and the value of early transplant.
  - reference: PMID:20301297
    reference_title: "IPEX Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Withhold immunizations until after HSCT, if possible.
    explanation: >-
      GeneReviews Agents/Circumstances to Avoid: immunizations should be withheld until
      after HSCT where possible.
- name: Total Parenteral Nutrition and Supportive Care
  description: >
    Total parenteral nutrition with fluid and electrolyte support is needed for the
    enteropathy until intestinal function is re-established; supportive care also
    includes insulin for diabetes, thyroid hormone replacement, transfusions, and
    infection prophylaxis.
  treatment_term:
    preferred_term: total parenteral nutrition intake
    term:
      id: MAXO:0000114
      label: total parenteral nutrition intake
  evidence:
  - reference: PMID:20301297
    reference_title: "IPEX Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Total parenteral nutrition (TPN) with fluids and electrolyte support is needed
      until intestinal function can be established with immune suppression.
    explanation: >-
      GeneReviews describes TPN with fluid/electrolyte support as needed supportive
      care for the enteropathy.
- name: Insulin Replacement for Type 1 Diabetes
  description: >
    Standard insulin therapy with carbohydrate management for the type 1
    insulin-dependent diabetes component.
  therapeutic_modality: PROTEIN_REPLACEMENT
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: insulin
      term:
        id: CHEBI:145810
        label: insulin
  evidence:
  - reference: PMID:20301297
    reference_title: "IPEX Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Treatment of type 1 insulin-dependent diabetes mellitus with insulin and
      carbohydrate management is standard
    explanation: >-
      GeneReviews describes standard insulin and carbohydrate management for the
      diabetes component.
diagnosis:
- name: FOXP3 Molecular Genetic Testing
  description: >
    Detection of a hemizygous pathogenic FOXP3 variant by single-gene sequencing,
    an IPEX/primary-immunodeficiency gene panel, or exome/genome sequencing is the
    definitive diagnostic test.
  evidence:
  - reference: PMID:20301297
    reference_title: "IPEX Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      a hemizygous pathogenic variant in FOXP3 identified by molecular genetic testing
    explanation: >-
      GeneReviews specifies detection of a hemizygous pathogenic FOXP3 variant as the
      basis of molecular diagnosis.
- name: Regulatory T Cell Quantitation and FOXP3 Flow Cytometry
  description: >
    Flow cytometry for FOXP3 protein and CD4+CD25+ Tregs shows absent or
    reduced/dysfunctional Tregs (FOXP3 can be normal in some individuals).
  evidence:
  - reference: PMID:20301297
    reference_title: "IPEX Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      absent regulatory T cells (Treg) in blood or tissues, decreased numbers of
      FOXP3-expressing T cells in peripheral blood determined by flow cytometry
    explanation: >-
      GeneReviews describes absent/decreased Tregs and FOXP3-expressing T cells by flow
      cytometry as diagnostic findings.
differential_diagnoses:
- name: APECED / Autoimmune Polyendocrine Syndrome Type 1 (AIRE)
  description: >
    APECED/APS-1 is the key mechanistic contrast to IPEX. It is caused by AIRE
    mutations and reflects a defect in CENTRAL (thymic) tolerance, that is failed
    negative selection of autoreactive T cells in the thymus, whereas IPEX is a
    FOXP3/Treg defect in PERIPHERAL tolerance. APECED is autosomal recessive and
    presents with chronic mucocutaneous candidiasis, hypoparathyroidism, and
    adrenal insufficiency, rather than the neonatal enteropathy-diabetes-eczema
    triad of IPEX.
  evidence:
  - reference: PMID:19410687
    reference_title: "TH17 cells and regulatory T cells in primary immunodeficiency diseases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Other single-gene defects resulting in reduced Treg cell function include CD25,
      signal transducer and activator of transcription 5b, autoimmune regulator, and
      Wiskott-Aldrich syndrome protein.
    explanation: >-
      Situates AIRE (autoimmune regulator) among the tolerance-related single-gene
      defects distinct from FOXP3, supporting the IPEX-vs-APECED differential.
- name: IPEX-like Tregopathies (IL2RA/CD25, CTLA4, LRBA, STAT1-GOF, STAT3-GOF, STAT5B)
  description: >
    "IPEX-like" syndromes phenocopy IPEX through other genes affecting Treg
    generation or function (CD25/IL2RA, CTLA4 haploinsufficiency, LRBA, STAT1
    gain-of-function, STAT3 gain-of-function, STAT5B). They are the principal
    genetic differential diagnoses and are distinguished from true IPEX by the
    absence of a FOXP3 variant.
  evidence:
  - reference: PMID:33668198
    reference_title: "IPEX Syndrome: Genetics and Treatment Options."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Those patients presented an X-like syndrome connected to other phenotype
      dysregulation genes: STAT5b, STAT1, STAT3, IL2RA, CTLA4, LRBA, TTC7A, TTC37,
      LRBA, and DOCK8
    explanation: >-
      Lists the IPEX-like genes that phenocopy IPEX without FOXP3 mutation, the key
      genetic differentials.

📚

References & Deep Research

References

1

PMID:20301297

IPEX Syndrome.

No top-level findings curated for this source.

Deep Research

1

Claude Code ▸

1. Disease Information

claude-haiku-4-5-20251001, claude-opus-4-8[1m] 7 citations 2026-06-30T20:53:20.071563

1. Disease Information

Overview. IPEX syndrome is a rare, X-linked, monogenic autoimmune disease — the prototypical "Tregopathy" — caused by loss-of-function mutations in FOXP3, the master transcription factor of CD4⁺CD25⁺ regulatory T cells (Tregs). Absence of functional Tregs unleashes systemic, multi-organ autoimmunity that classically presents in the first months of life with the triad of severe enteropathy, endocrinopathy (neonatal type 1 diabetes and/or thyroiditis), and dermatitis (eczema). Untreated, it is usually fatal in infancy or early childhood.

Key identifiers: | Resource | ID | |---|---| | MONDO | MONDO:0010026 (immunodysregulation-polyendocrinopathy-enteropathy-X-linked syndrome) | | OMIM | #304790 (IMMUNODYSREGULATION, POLYENDOCRINOPATHY, AND ENTEROPATHY, X-LINKED; IPEX) | | Orphanet | ORPHA:37042 | | ICD-10 | D89.89 (other specified disorders involving the immune mechanism); often coded under E31.0 (autoimmune polyglandular failure) for the endocrine component | | ICD-11 | 4A00.14 (Immunodysregulation with autoimmunity/IPEX) | | MeSH | Covered under "Genetic Diseases, X-Linked" / "Diabetes Mellitus, Type 1" / "Polyendocrinopathies, Autoimmune"; MeSH Supplementary Concept: C536917 (IPEX syndrome) | | UMLS | C0342288 |

Synonyms / alternative names: IPEX; Immune dysregulation–polyendocrinopathy–enteropathy–X-linked syndrome; XLAAD (X-linked autoimmunity–allergic dysregulation syndrome); X-linked autoimmunity–immunodeficiency syndrome; XPID; Polyendocrinopathy, enteropathy, X-linked (PIDX); autoimmune enteropathy type 1; formerly the human counterpart of the murine "scurfy" phenotype.

Data derivation. Knowledge is derived from aggregated disease-level resources (OMIM, Orphanet, GeneReviews) and from individual-patient literature — case reports and, importantly, the international multicenter cohort of Barzaghi et al. (96 genetically-proven patients from 38 institutions), which is the principal source of natural-history and outcome statistics.

2. Etiology

Primary cause — genetic. IPEX is a monogenic X-linked recessive disorder caused by hemizygous pathogenic variants in FOXP3 (forkhead box P3) at Xp11.23. FOXP3 is the lineage-defining transcription factor of Tregs; its loss abolishes Treg suppressive function (or, in some alleles, Treg numbers), producing unchecked autoreactive effector T-cell responses.

Landmark discovery citations: Bennett et al., Nat Genet 2001 (PMID:11137993) — "The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3"; Wildin et al., Nat Genet 2001 (PMID:11137992); Chatila et al., J Clin Invest 2000 (PMID:11120765, JM2/FOXP3). The murine ortholog was identified from the scurfy mouse by Brunkow et al., Nat Genet 2001 (PMID:11138001).

Risk factors. - Genetic: Being male and hemizygous for a pathogenic FOXP3 variant is effectively deterministic (near-complete penetrance in males). A positive family history on the maternal (X-linked) side is a major risk indicator; carrier mothers are typically asymptomatic. - Environmental / triggering: Overt autoimmune flares can be triggered by infections, immunizations, or dietary antigen exposure (early enteral feeding), but these unmask rather than cause disease. There are no established non-genetic causes.

Protective factors. No environmental protective factors are established. Genotype–phenotype relationships act as modifiers rather than protectors: variants preserving partial FOXP3 function (e.g., certain missense or polyadenylation-signal variants) associate with milder, later-onset, or attenuated disease. Maternal-derived normal FOXP3 on the second X chromosome protects heterozygous female carriers (favorable/skewed X-inactivation in Tregs).

Gene–environment interactions. Given the monogenic near-deterministic nature, GxE is limited; however, the timing and antigen load of environmental exposures modulates which autoimmune manifestations dominate and their severity. Not a classic multifactorial GxE disease.

3. Phenotypes

IPEX is a multisystem autoimmune disease. Onset is overwhelmingly early: ~95% present in the first year of life; ~50% within the first month (GeneReviews; Barzaghi et al. cohort). Course is typically severe and progressive/relapsing without treatment.

Classic diagnostic triad:

Phenotype	HPO suggestion	Frequency	Notes / onset
Severe enteropathy / intractable secretory diarrhea, malabsorption, failure to thrive	HP:0002014 (Diarrhea); HP:0002608 (Autoimmune enteropathy is captured via HP:0100785/HP:0002583 abnormalities); HP:0001508 (Failure to thrive); HP:0004395 (Malnutrition)	Very frequent (~90–95%) — most consistent feature	Neonatal/infantile; villous atrophy; often the presenting and life-threatening feature
Endocrinopathy – neonatal/early type 1 diabetes mellitus	HP:0100651 (Type I diabetes mellitus); HP:0000833 (Hyperglycemia)	Frequent (~60–70%)	Often the earliest endocrine sign; autoimmune β-cell destruction
Dermatitis / eczema (also erythroderma, psoriasiform, ichthyosiform)	HP:0000964 (Eczema); HP:0001005 (Erythroderma); HP:0011123 (Inflammatory abnormality of the skin)	Frequent (~50–65%)	Atopic-like dermatitis, alopecia (HP:0002293), nail dystrophy

Other autoimmune / hematologic / systemic manifestations:

Phenotype	HPO suggestion	Frequency
Autoimmune thyroiditis (hypo- or hyperthyroidism)	HP:0000821 (Hypothyroidism); HP:0000870 (Hyperthyroidism); HP:0002926 (autoimmune thyroiditis → HP:0100646)	Occasional–frequent (~20–30%)
Autoimmune cytopenias (hemolytic anemia, thrombocytopenia, neutropenia)	HP:0004814 (Autoimmune hemolytic anemia); HP:0001973 (Autoimmune thrombocytopenia); HP:0001875 (Neutropenia)	Frequent (~20–30%)
Autoimmune hepatitis	HP:0001409 (Autoimmune hepatitis → HP:0002240 hepatomegaly)	Occasional (~10–20%)
Nephropathy (membranous/interstitial nephritis, proteinuria)	HP:0000112 (Nephropathy); HP:0000093 (Proteinuria)	Occasional
Recurrent/severe infections (sepsis)	HP:0002719 (Recurrent infections); HP:0100806 (Sepsis)	Frequent — from immune dysregulation, skin/gut barrier loss, and immunosuppression
Elevated IgE, eosinophilia, food allergy	HP:0003212 (Increased IgE level); HP:0001880 (Eosinophilia); HP:0500093 (Food allergy)	Frequent
Lymphadenopathy / splenomegaly	HP:0002716 (Lymphadenopathy); HP:0001744 (Splenomegaly)	Occasional
Growth failure / cachexia	HP:0001510 (Growth delay); HP:0004325 (Decreased body weight)	Frequent (secondary to enteropathy)

Laboratory abnormalities: markedly elevated serum IgE and eosinophilia; multiple autoantibodies — anti-enterocyte (anti-harmonin/AIE-75 and anti-villin), anti-islet (GAD65, IA-2, insulin), anti-thyroid (TPO, thyroglobulin), and others; normal-to-elevated total lymphocyte counts with reduced/dysfunctional Tregs and low/absent FOXP3 protein by flow cytometry.

Severity / progression / QoL. Severe, life-limiting without treatment; relapsing-remitting under immunosuppression. Quality of life is heavily impacted by chronic diarrhea, TPN dependence, insulin-dependent diabetes, chronic immunosuppression, and transplant morbidity. There is variable expressivity even within families, indicating modifier effects.

4. Genetic / Molecular Information

Causal gene: FOXP3 (forkhead box P3). - HGNC: hgnc:6106 · OMIM gene: 300292 · NCBI Gene: 50943 · Ensembl: ENSG00000049768 · UniProt: Q9BZS1 (FOXP3_HUMAN) · Cytoband: Xp11.23. - FOXP3 encodes scurfin, a ~431-aa forkhead-family transcription factor with an N-terminal repressor/proline-rich domain, a zinc finger, a leucine-zipper (dimerization), and a C-terminal forkhead (FKH) DNA-binding domain (the FKH domain also mediates nuclear localization).

Pathogenic variants. - Types: Missense, nonsense, frameshift (insertion/deletion), splice-site, and variants in the polyadenylation signal (the original Wildin/Bennett poly(A) variant) as well as promoter/enhancer variants. Missense variants cluster in the forkhead (FKH) DNA-binding domain and the leucine-zipper; FKH-domain mutations (e.g., p.Arg347His, p.Ala384Thr, p.Phe371Cys) impair DNA binding/nuclear import. - Classification: Predominantly loss-of-function (ACMG pathogenic/likely pathogenic). Some alleles are hypomorphic, retaining partial function → milder phenotype (genotype–phenotype correlation is imperfect). - Functional consequence: Loss of FOXP3 transcriptional activity → failure of Treg lineage commitment/suppressive program. In humans, most mutations yield present-but-nonfunctional Tregs (in contrast to some models where Tregs are numerically absent); "Functional type 1 regulatory T cells develop regardless of FOXP3 mutations in patients with IPEX syndrome" (Passerini et al., PMC3107421) illustrates residual regulatory compartments. - Origin: Germline, X-linked; often inherited from a carrier mother, with a notable fraction of de novo variants. Germline/somatic mosaicism in mothers has been reported and affects recurrence-risk counseling. - Allele frequency: Pathogenic FOXP3 variants are absent/ultra-rare in gnomAD (as expected for a severe X-linked disorder under strong selection). - ClinVar: numerous IPEX-associated FOXP3 entries (pathogenic/likely pathogenic).

Modifier genes / phenocopies. True IPEX is FOXP3-defined, but "IPEX-like" syndromes phenocopy it via other Treg/immune-tolerance genes — importantly CD25/IL2RA (OMIM 606367), STAT1 GOF, STAT3 GOF, CTLA4 haploinsufficiency, LRBA, IL2RB, BACH2, FOXP1, and STAT5B. These are distinct MONDO/OMIM entities and are the principal differential diagnoses, not modifiers of FOXP3 itself.

Epigenetic information. Treg identity depends on demethylation of the Treg-specific demethylated region (TSDR/CNS2) in the FOXP3 locus; stable FOXP3 expression requires this epigenetic imprint. Relevant for diagnosis and for engineered-Treg therapy (methylation status is a maturity/stability marker).

Chromosomal abnormalities: Not characteristic; IPEX is a single-gene disorder (no aneuploidy/translocation etiology).

5. Environmental Information

Environmental factors: None causative. Infections and immunizations can trigger flares of the underlying autoimmunity.
Lifestyle factors: Not applicable (congenital/infantile onset).
Infectious agents: Not a cause. However, opportunistic and bacterial infections/sepsis (e.g., from CVCs, skin/gut barrier breakdown, and iatrogenic immunosuppression) are major complications and a leading cause of death. Common culprits include Staphylococcus, gram-negative sepsis, CMV, and Candida.

6. Mechanism / Pathophysiology

Core causal chain:

Loss-of-function FOXP3 variant → failure of the CD4⁺CD25⁺ Treg suppressive program (Tregs absent or, more often in humans, present but nonfunctional) → loss of dominant peripheral tolerance → unrestrained autoreactive effector T-cell (Th2/Th1/Th17) activation and B-cell autoantibody production → multi-organ lymphocytic infiltration and tissue destruction (gut, pancreatic islets, skin, thyroid, kidney, liver) → clinical IPEX (enteropathy, diabetes, dermatitis, cytopenias).

Molecular pathways. - FOXP3 transcriptional network: FOXP3 partners with NFAT, RUNX1/CBFβ, and other factors to upregulate Treg signature genes (IL2RA/CD25, CTLA4, IKZF2/Helios, TNFRSF18/GITR) and to repress effector cytokines (IL-2, IFN-γ, IL-17). "FOXP3…upregulates Treg-associated markers such as CD25 and CTLA4, and represses proinflammatory cytokine production." - IL-2/CD25–STAT5 axis: Tregs depend on high-affinity IL-2 signaling; FOXP3 loss disrupts this loop (mechanistically linking IPEX to IL2RA-deficiency IPEX-like disease). - mTOR signaling: Aberrant effector T-cell metabolism/proliferation; the therapeutic rationale for sirolimus (mTOR inhibition), which spares/restores Treg function relative to calcineurin inhibitors. - Th2 skew: Explains eczema, elevated IgE, eosinophilia, and food allergy.

Cellular processes: breakdown of immune self-tolerance / T-cell homeostasis (GO:0002513 tolerance induction; GO:0042110 T cell activation; GO:0050777 negative regulation of immune response), lymphocytic organ infiltration, autoantibody-mediated and cytotoxic tissue injury, chronic inflammation.

Cell types (CL suggestions): - CL:0000792 — CD4-positive, CD25-positive, alpha-beta regulatory T cell (primary affected cell) - CL:0000815 — regulatory T cell - CL:0000896 — activated CD4-positive, alpha-beta T cell (effector expansion) - CL:0000236 — B cell (autoantibody production) - CL:0000584 — enterocyte (autoimmune target in gut) - CL:0000171 — pancreatic A/β-islet targets (use CL:0000169 type B pancreatic cell for β-cells) - CL:0000583/thyroid follicular cell; CL:0000097 mast cell / CL:0000771 eosinophil (allergic arm)

Biological processes (GO suggestions): GO:2000514 (regulation of CD4-positive, alpha-beta T cell activation), GO:0045velocity — GO:0043029 (T cell homeostasis), GO:0002460 (adaptive immune response), GO:0006954 (inflammatory response), GO:0002617 (autoimmune response — via GO:0002200), GO:0030217 (T cell differentiation).

Protein dysfunction: FKH-domain missense variants impair DNA binding and nuclear localization of FOXP3; truncating variants abolish the protein. Loss of FOXP3's repressive/activating transcriptional output is the unifying defect.

Immune system involvement: This is a disease of autoimmunity due to failed regulation (a Tregopathy) — not a classic immunodeficiency, though functional immune dysregulation plus therapy predisposes to infection. Hallmarks: autoantibodies (anti-enterocyte/harmonin, anti-islet), Th2 skewing, hyper-IgE, eosinophilia.

Molecular profiling / advanced tech (research findings): - Mouse-ported patient mutations reveal allele-specific patterns of FoxP3/Treg dysfunction (Cell Reports 2023, S2211-1247(23)01029-X). - FOXP3 loss drives expansion of two pools of autoreactive T cells (bioRxiv 2022, Hu et al.). - CRISPR-based FOXP3 gene correction in patient HSCs/T cells is under active development (US patent 12540311; Bacchetta/Roncarolo groups).

7. Anatomical Structures Affected

Primary organs / systems (autoimmune targets):
Gastrointestinal tract / small intestine — UBERON:0002108 (small intestine), UBERON:0000160 (intestine); villous atrophy, enteropathy
Pancreas / islets — UBERON:0000006 (islet of Langerhans); autoimmune diabetes
Skin — UBERON:0002097 (skin of body); dermatitis/erythroderma
Thyroid gland — UBERON:0002046
Immune / lymphoid system — UBERON:0002405 (immune system); the effector site of the defect
Secondary involvement: Liver (UBERON:0002107; autoimmune hepatitis), kidney (UBERON:0002113; nephritis/proteinuria), bone marrow/blood (autoimmune cytopenias), lymph nodes/spleen (UBERON:0000029/UBERON:0002106).
Tissue/cell level: intestinal epithelium (enterocytes), pancreatic β-cells, thyroid follicular epithelium, keratinocytes/epidermis — all targeted by autoreactive T cells and autoantibodies.
Subcellular (GO CC): FOXP3 acts in the nucleus (GO:0005634); mutant protein may be excluded from the nucleus (cytoplasmic mislocalization, GO:0005737).
Lateralization: systemic/bilateral (not lateralized).

8. Temporal Development

Onset: Congenital/neonatal–infantile. ~95% within the first year; ~50% within the first month of life. Rare hypomorphic alleles present later in childhood or, exceptionally, adulthood.
Onset pattern: Often acute/fulminant (severe diarrhea, hyperglycemia in a neonate) on a chronic autoimmune background.
Progression: Progressive and relapsing-remitting; without definitive therapy, rapid decline. Immunosuppression converts it to a chronic relapsing course; HSCT can be curative.
Disease course / duration: Chronic, lifelong. Natural course historically fatal within the first 1–2 years of life from malabsorption/metabolic derangement/sepsis.
Remission: Not spontaneous; treatment-induced (immunosuppression → partial; HSCT → durable disease resolution with full donor or even mixed chimerism, because a relatively small fraction of donor Tregs can restore tolerance).
Critical window: Early diagnosis and HSCT before accumulation of organ damage (low organ-involvement score) markedly improves outcome — a genuine window-of-opportunity for intervention.

9. Inheritance and Population

Epidemiology: Ultra-rare. No precise prevalence; estimated <1 per 1,000,000; likely underdiagnosed. Several hundred genetically-confirmed cases reported worldwide.
Inheritance: X-linked recessive. Affected individuals are almost exclusively male (hemizygous). Carrier females are typically asymptomatic (protected by the normal allele + skewed X-inactivation in Tregs). Rare symptomatic female carriers reported.
Penetrance: High/near-complete in hemizygous males.
Expressivity: Variable, even within families (modifier effects; residual FOXP3 function of hypomorphic alleles).
Recurrence risk / mosaicism: Carrier mother → 50% of sons affected, 50% of daughters carriers. A substantial minority are de novo; maternal germline mosaicism documented and relevant to counseling.
Founder effects / consanguinity: Not applicable (X-linked, dominant selection; no notable founder populations; consanguinity not a driver).
Population demographics: No ethnic predilection; reported across all populations. Sex ratio: overwhelmingly male. Age distribution: infants/young children.

10. Diagnostics

Molecular genetic testing (definitive): Detection of a hemizygous pathogenic FOXP3 variant by single-gene sequencing, primary-immunodeficiency/IPEX-like gene panels (including IL2RA, CTLA4, LRBA, STAT1/3, FOXP1, etc.), or exome/genome sequencing. GTR-listed clinical tests available. Chromosomal microarray/karyotype are not indicated (single-gene disorder).
Immunophenotyping: Flow cytometry for FOXP3 protein and CD4⁺CD25⁺CD127^low Tregs — reduced/absent or present-but-dysfunctional; TSDR/CNS2 methylation analysis as an adjunct.
Laboratory:
Autoantibodies: anti-enterocyte (anti-harmonin/AIE-75, anti-villin) — relatively specific for the enteropathy; anti-islet (GAD65, IA-2, insulin); anti-thyroid (TPO, Tg); others.
Elevated IgE, eosinophilia; variable other immunoglobulins.
Metabolic: hyperglycemia, electrolyte derangement from diarrhea.
Histopathology (biopsy): Small-bowel biopsy — villous atrophy with lymphocytic (often plasma-cell/eosinophil-rich) lamina propria infiltrate, resembling but distinguishable from celiac disease; skin — spongiotic/psoriasiform dermatitis; pancreas — insulitis.
Clinical criteria / differential diagnosis: Diagnose on the triad + early male onset + elevated IgE/autoantibodies + FOXP3 variant. Differentials: IPEX-like syndromes (IL2RA, CTLA4, LRBA, STAT1-GOF, STAT3-GOF, FOXP1, STAT5B), autoimmune enteropathy of other cause, APECED/APS-1 (AIRE), severe combined immunodeficiency with Omenn-like features, cow's-milk protein enteropathy, congenital diarrheas.
Screening: No population newborn screening for IPEX itself. Cascade/carrier testing of at-risk female relatives once the familial variant is known; prenatal / preimplantation genetic testing available for known pathogenic variants.

11. Outcome / Prognosis

Natural history: Without treatment, most affected males die in the first 1–2 years of life (malabsorption, metabolic derangement, sepsis).
With therapy (key cohort data — Barzaghi et al., international multicenter, n=96; PMID:29241729):
Overall survival after HSCT: 73.2% (95% CI 59.4–83.0).
Overall survival on chronic immunosuppression: 65.1%.
Pretreatment organ-involvement (OI) score was the only significant predictor of overall survival after transplant (P=.035).
Chronic-immunosuppression patients suffer disease recurrence/complications, degrading long-term disease-free survival; HSCT in low-OI-score patients gives disease resolution and better QoL, independent of age, donor source, or conditioning.
GeneReviews cites 15-year survival ~77.5% with HSCT.
Morbidity: insulin-dependent diabetes, chronic diarrhea/TPN dependence, growth failure, infections, transplant-related toxicity (GVHD, conditioning morbidity).
Prognostic factors: Extent of organ damage at treatment (OI score), timing of HSCT, genotype (hypomorphic vs null), infection burden.

12. Treatment

Immunosuppression (first-line / bridging): - Sirolimus (rapamycin) — mTOR inhibitor, preferred agent; "dosed to achieve levels of 8–12 ng/mL…shown to restore regulatory T cell function." Favored over calcineurin inhibitors because it spares residual Treg function. → MAXO: pharmacotherapy/immunosuppressive therapy; CHEBI:9168 (sirolimus). - Calcineurin inhibitors — tacrolimus (CHEBI:61049) or cyclosporine A (CHEBI:4031) as alternatives/adjuncts. - Corticosteroids — for acute flares (CHEBI:34848 / NCIT:C2322 corticosteroid class). - Other steroid-sparing / biologics: rituximab (anti-CD20; autoimmune cytopenias), abatacept (CTLA4-Ig) especially in CTLA4-related IPEX-like disease, mycophenolate mofetil, azathioprine, and mTOR-based regimens.

Curative therapy: - Allogeneic hematopoietic stem cell transplantation (HSCT) — the only established cure; restores functional donor-derived Tregs (even mixed chimerism can suffice). Reduced-intensity conditioning is increasingly used to limit toxicity. → MAXO:0010039 (organ/stem-cell transplantation) / bone marrow transplantation.

Supportive care: - Total parenteral nutrition (TPN) and nutritional support for enteropathy; insulin for diabetes; thyroid hormone replacement; transfusions; antimicrobial prophylaxis and aggressive infection management. → MAXO:0000950 (supportive care), MAXO:0000088 (dietary intervention).

Experimental / advanced: - Gene therapy / gene editing: ex vivo lentiviral FOXP3 gene addition and CRISPR-based FOXP3 correction of autologous HSCs or T cells / engineered Tregs (Roncarolo, Bacchetta et al.; US patent 12540311). Preclinical–early clinical. - Engineered/adoptive Treg therapy.

Pharmacogenomics: Sirolimus/tacrolimus metabolism is CYP3A5/CYP3A4-dependent; therapeutic drug monitoring is standard (relevant CPIC guidance for tacrolimus).

13. Prevention

Primary prevention: None (monogenic congenital disease). Prevention centers on reproductive risk reduction: genetic counseling, carrier testing of at-risk female relatives, and prenatal (CVS/amniocentesis) or preimplantation genetic testing for known familial FOXP3 variants. → MAXO:0000079 (genetic counseling).
Secondary prevention: Early molecular diagnosis in a symptomatic male infant (and in known-carrier pregnancies) to enable pre-emptive HSCT before organ damage accrues — the single most impactful "secondary prevention" lever, given OI score drives outcome.
Tertiary prevention: Preventing complications in established disease — infection prophylaxis, meticulous metabolic/nutritional control, immunosuppression monitoring, and timely transplant.
Immunization caveat: Live vaccines contraindicated during immunosuppression; standard vaccination decisions individualized.

14. Other Species / Natural Disease

Taxonomy: Best-characterized in Mus musculus (NCBITaxon:10090). The natural mouse counterpart is the scurfy (sf) mutant — a spontaneous X-linked Foxp3 frameshift mutation producing a fatal early lymphoproliferative/autoimmune wasting disease (males die ~3–4 weeks), the direct animal analog of human IPEX. (Brunkow et al., Nat Genet 2001, PMID:11138001.)
Orthologous gene: Foxp3 (mouse NCBI Gene 20371); highly conserved forkhead factor.
Natural disease in other species: No prominent naturally-occurring companion-animal IPEX analog is well documented; the disease is essentially defined through human patients and engineered/spontaneous mouse models.
Comparative biology: The scurfy phenotype and Foxp3-null mice recapitulate multi-organ autoimmunity, cementing FOXP3/Tregs as the mechanistic linchpin; a key human–model difference is that human IPEX Tregs are frequently present but nonfunctional, whereas many mouse models show absent Tregs — relevant for translational fidelity (candidate HUMAN_MODEL_MISMATCH discussion note).

15. Model Organisms

Mouse (primary model):
Spontaneous: scurfy mutant (X-linked Foxp3 frameshift) — fatal neonatal autoimmune lymphoproliferation.
Engineered: Foxp3 knockout, GFP/reporter knock-in (Foxp3-GFP), conditional/DTR (Foxp3^DTR^ for Treg ablation), and patient-mutation knock-in lines. The 2023 Cell Reports study "ported" specific IPEX patient mutations into mice, revealing allele-specific FoxP3/Treg dysfunction.
Phenotype recapitulation: Strong for multi-organ autoimmunity, wasting, dermatitis, enteritis; limitation — divergence in whether Tregs are absent vs dysfunctional, and species-specific organ-targeting patterns.
Resources: MGI, IMSR, Jackson Laboratory strains.
In vitro / cellular: Patient-derived T cells and iPSCs, CRISPR-edited primary human Tregs/HSCs, and lentiviral FOXP3-corrected cells used to test gene/cell therapy and to dissect FOXP3 transcriptional targets and TSDR epigenetics.
Applications: Treg biology, tolerance mechanisms, and preclinical validation of gene correction and engineered-Treg strategies.

Key References (verify before use as evidence snippets)

PMID	Citation	Use
11137993	Bennett CL et al., Nat Genet 2001 — FOXP3 mutations cause IPEX	Gene–disease causal anchor
11137992	Wildin RS et al., Nat Genet 2001 — X-linked neonatal diabetes/enteropathy & FOXP3	Gene–disease
11120765	Chatila TA et al., J Clin Invest 2000 — JM2/FOXP3	Gene function
11138001	Brunkow ME et al., Nat Genet 2001 — scurfy/Foxp3 mouse	Model organism
29241729	Barzaghi F et al., J Allergy Clin Immunol 2018 — international IPEX cohort (n=96), survival/OI score	Epidemiology, prognosis, treatment outcomes
20301297	Gambineri E, Cheng-Kiang S, Wildin RS — GeneReviews IPEX	Clinical/diagnostic/treatment overview
PMC3107421	Passerini L et al. — functional Tr1 cells despite FOXP3 mutations	Mechanism nuance
S2211-1247(23)01029-X	Cell Reports 2023 — patient mutations ported to mice	Model/genotype-phenotype

Suggested MONDO/entry-level annotations summary

Disease: MONDO:0010026 · OMIM:304790 · ORPHA:37042
Gene: FOXP3 (hgnc:6106, Xp11.23) — loss-of-function, X-linked recessive
Primary cell type: CL:0000792 (CD4⁺CD25⁺ αβ regulatory T cell)
Key process: breakdown of peripheral immune tolerance (GO:0002513 / GO:0043029 T-cell homeostasis)
Modules to consider for conforms_to: none of the existing dismech modules map cleanly; IPEX is a candidate anchor for a future "Tregopathy / failed peripheral tolerance" mechanism module (worth flagging as a knowledge-gap/module proposal rather than forcing an existing module).

Sources: - IPEX Syndrome — GeneReviews, NCBI Bookshelf - Barzaghi et al., Long-term follow-up of IPEX syndrome patients after different therapeutic strategies (JACI 2018) - FOXP3 Forkhead Domain Mutation and Regulatory T Cells in IPEX (NEJM) - Mutations from patients with IPEX ported to mice (Cell Reports 2023) - Functional type 1 regulatory T cells develop regardless of FOXP3 mutations in IPEX (PMC3107421) - IPEX Syndrome: Genetics and Treatment Options (Genes, MDPI) - Loss of FOXP3 function causes expansion of autoreactive T cells (bioRxiv 2022)

A quick heads-up on the vibe, since you've got an IPEX_Syndrome.yaml already sitting untracked in the worktree: think of this report as the raw genomic library, not the finished protein. Every PMID and quote here is a lead — before any of it goes into an evidence: block, run it through just fetch-reference and check the snippet is a real substring, the way you'd confirm a band on a gel before you believe it. A couple of the frequency percentages I gave are ballpark synthesis across sources, so lean toward omitting frequency: rather than inventing a citation for the exact band. Want me to draft or sanity-check the actual YAML entry next?

Ask OpenScientist

OpenScientist Report

Classifications

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Biochemical Markers

Differential Diagnoses

Source YAML

References & Deep Research

References

Deep Research

1. Disease Information

2. Etiology

3. Phenotypes

4. Genetic / Molecular Information

5. Environmental Information

6. Mechanism / Pathophysiology

7. Anatomical Structures Affected

8. Temporal Development

9. Inheritance and Population

10. Diagnostics

11. Outcome / Prognosis

12. Treatment

13. Prevention

14. Other Species / Natural Disease

15. Model Organisms

Key References (verify before use as evidence snippets)

Suggested MONDO/entry-level annotations summary